Source: Pantoro
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Pantoro (ASX:PNR) enters an agreement with Mineral Resources (ASX:MIN) to divest 100 per cent of its lithium, nickel, copper, and cobalt rights at the Norseman gold project in WA
  • This deal is valued at up to $60 million
  • Pantoro will also receive a two per cent net smelter royalty on all nickel, copper, and cobalt recovered, along with a 0.75 per cent FOB lithium royalty
  • PNR is up 20.5 per cent, trading at 4.7 cents at 3:47 pm AEDT

Pantoro (ASX:PNR) has entered into a binding agreement with Mineral Resources (ASX:MIN) to divest 100 per cent of its lithium, nickel, copper, and cobalt rights at the Norseman gold project in Westen Australia.

This deal is valued at up to $60 million, including a $30 million upfront cash payment, payable within five days of executing the binding term sheet.

In addition, there is a deferred payment of $30 million, payable upon the final investment decision to commence a nickel, copper, and/or cobalt mining operation.

Pantoro will also receive a two per cent net smelter royalty on all nickel, copper, and cobalt recovered, along with a 0.75 per cent FOB lithium royalty.

Both royalties are payable upon meeting specific Mineral Resource thresholds.

Pantoro retains ownership of the tenure and holds all rights to precious and other base metal and battery minerals over the entire tenement package.

“This transaction provides Pantoro with strong immediate value for minerals which have not yet been identified in economic quantities at Norseman,” PNR Managing Director Paul Cmrlec said.

PNR was up 20.5 per cent, trading at 4.7 cents at 3:47 pm AEDT.

PNR by the numbers
More From The Market Online
The Market Online Video

Tuesday’s HotCopper Trends: Pancontinental price buckles, Advance hits gold | March 18, 2025

The ASX has been up 0.3% at 7,877 points.
The Market Online Video

Expert Exchange: Saul Eslake breaks down the risks of investing in the ASX

Like any investment, share market investing has a risk and reward-relationship.
A huge ship built by Austal cruises through the blue ocean.

Take two: Korea’s Hanwha hasn’t given up on grabbing Austal stake just yet

Heavyweight South Korean business conglomerate Hanwha Group is taking another swing at Austal Ltd (ASX:ASB) half a year after its last takeover play
3D image of ovarian cancer

CLEO Diagnostics kicks off IP transfer for ovarian cancer blood tests to US manufacturers

CLEO Diagnostics has commenced the 'technology transfer' process to a US-based manufacturing partner ahead of commercialisation.